Orphan drugs accounted for only 7.9% of total drug sales in the U.S. in 2016, according to a recent QuintilesIMS study, but have accounted for more than 40% of new molecular entity approvals over...
Pfizer announced earlier this month that it is considering strategic alternatives to its consumer healthcare business. So what options may be ahead? The over-the-counter (OTC) drug market has seen...
